Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M252,050Revenue $M51,752Net Margin (%)37.8Altman Z-Score3.3
Enterprise Value $M269,517EPS $8.0Operating Margin %19.6Piotroski F-Score5
P/E(ttm)14.4Beneish M-Score-2.3Pre-tax Margin (%)21.5Higher ROA y-yY
Price/Book3.210-y EBITDA Growth Rate %4.8Quick Ratio0.6Cash flow > EarningsN
Price/Sales4.95-y EBITDA Growth Rate %-0.7Current Ratio0.8Lower Leverage y-yY
Price/Free Cash Flow24.9y-y EBITDA Growth Rate %5.9ROA % (ttm)15.1Higher Current Ratio y-yN
Dividend Yield %2.6PEG--ROE % (ttm)26.6Less Shares Outstanding y-yY
Payout Ratio %66.0Shares Outstanding M2,415ROIC % (ttm)10.3Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSKahn Brothers 2015-06-30 Reduce-0.05%$98.34 - $105.5
($102.32)
$ 104.362%Reduce 9.12%28,143
NVSKen Fisher 2015-06-30 Add0.01%$98.34 - $105.5
($102.32)
$ 104.362%Add 1.08%6,054,640
NVSDodge & Cox 2015-03-31 Reduce-0.02%$91.67 - $103
($98.99)
$ 104.365%Reduce 0.58%50,032,795
NVSTweedy Browne 2015-03-31 Reduce-0.01%$91.67 - $103
($98.99)
$ 104.365%Reduce 2.19%260,217
NVSHOTCHKIS & WILEY 2015-03-31 Sold Out -0.0031%$91.67 - $103
($98.99)
$ 104.365%Sold Out0
NVSMario Gabelli 2015-03-31 Add$91.67 - $103
($98.99)
$ 104.365%Add 2.61%9,840
NVSKen Fisher 2015-03-31 Reduce$91.67 - $103
($98.99)
$ 104.365%Reduce 0.29%5,990,224
NVSRuane Cunniff 2014-12-31 Sold Out $85.02 - $96.65
($92.56)
$ 104.3613%Sold Out0
NVSHOTCHKIS & WILEY 2014-09-30 Reduce-0.21%$85.25 - $94.8
($90.27)
$ 104.3616%Reduce 98.51%9,646
NVSRuane Cunniff 2014-09-30 Buy $85.25 - $94.8
($90.27)
$ 104.3616%New holding7,772
NVSHOTCHKIS & WILEY 2014-06-30 Reduce-0.52%$82.51 - $90.98
($87.73)
$ 104.3619%Reduce 71.80%649,519
NVSDodge & Cox 2014-06-30 Add0.4%$82.51 - $90.98
($87.73)
$ 104.3619%Add 10.04%51,102,219
NVSChris Davis 2013-09-30 Sold Out -0.01%$70.66 - $77.08
($73.84)
$ 104.3641%Sold Out0
NVSVanguard Health Care Fund 2013-06-30 Sold Out -0.2%$68.42 - $75.5
($72.61)
$ 104.3644%Sold Out0
NVSVanguard Health Care Fund 2013-03-31 Reduce-0.71%$63.3 - $71.32
($67.87)
$ 104.3654%Reduce 85.39%726,200
NVSKahn Brothers 2013-03-31 Reduce-0.1%$63.3 - $71.32
($67.87)
$ 104.3654%Reduce 21.03%33,456
NVSVanguard Health Care Fund 2012-12-31 Reduce-0.99%$58.97 - $63.96
($61.82)
$ 104.3669%Reduce 70.59%1,461,400
NVSDodge & Cox 2012-12-31 Add0.11%$58.97 - $63.96
($61.79)
$ 104.3669%Add 2.65%48,438,459
NVSKahn Brothers 2012-12-31 Add0.04%$58.97 - $63.96
($61.82)
$ 104.3669%Add 10.43%42,368
NVSHOTCHKIS & WILEY 2012-12-31 Reduce-0.02%$58.97 - $63.96
($61.82)
$ 104.3669%Reduce 1.98%2,313,613
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15595.73view

Quarterly/Annual Reports about NVS:

    News about NVS:

    Articles On GuruFocus.com
    Bill Frels' Stocks With Highest-Growing Yields Jun 26 2015 
    Bill Frels' Stocks With Growing Yields Jun 27 2015 
    Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
    Follow Bill Ackman in Valeant Pharmaceuticals Jun 19 2015 
    Billionaire George Soros Ups Two Stakes in First Quarter Jun 16 2015 
    Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
    Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
    8 Top Healthcare Stocks to Watch May 13 2015 
    Amgen Reports An Upbeat Q1 Earnings Apr 23 2015 
    Top Weighted Stocks in Tweedy Browne Global Value Fund's Portfolio Apr 22 2015 

    More From Other Websites
    5 Biotechs With Catalysts Coming This Week Aug 03 2015
    Valeant Pharmaceuticals International, Inc. Earnings Q2*, 2015 Aug 03 2015
    CSL completes Novartis flu vaccine deal Aug 02 2015
    Novartis completes divestiture of influenza vaccines business to CSL Limited for USD 275 million Aug 02 2015
    Amgen hikes 2015 forecast after 2Q increase in profit, sales Jul 30 2015
    Amgen hikes 2015 forecast after 2Q increase in profit, sales Jul 30 2015
    GlaxoSmithKline (GSK) Earnings Report: Q2 2015 Conference Call Transcript Jul 30 2015
    Glaxo Up on Q2 Earnings Beat, Revenues Rise, View Same - Analyst Blog Jul 30 2015
    Novartis’s Shares Fall after 2Q15 Earnings Jul 30 2015
    Valeant Pharmaceuticals International, Inc. Earnings Analysis: By the Numbers Jul 30 2015
    GSK Boosted by New Vaccines Jul 29 2015
    HIV/Aids treatments stand out as GSK promises 40-drug pipeline Jul 29 2015
    Why Sandoz Revenues Were Important for Novartis in 2Q15 Jul 29 2015
    GSK beats expectations as anti-HIV drugs lift sales Jul 29 2015
    GSK beats expectations with second-quarter results Jul 29 2015
    GSK earnings relief Jul 29 2015
    Novartis delivered solid performance in the second quarter, with strong innovation and progress on... Jul 29 2015
    Novartis Foundation confirms new members of its Board of trustees, including new Chairman Dr. Joerg... Jul 29 2015
    GSK flags up pipeline as HIV drugs help it beat profit forecasts Jul 29 2015
    Eli Lilly & Co. Earnings Analysis: By the Numbers Jul 29 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK